December 8, 2023
VIA EDGAR
Mr. Gary Newberry
Mr. Kevin Kuhar
Division of Corporate Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Madrigal Pharmaceuticals, Inc. |
Form 10-K for the Fiscal Year Ended December 31, 2022
File No. 001-33277
Dear Messrs. Newberry and Kuhar:
Madrigal Pharmaceuticals, Inc. (the “Company”) received a comment letter from the U.S Securities and Exchange Commission (the “SEC”) dated November 21, 2023 in regard to the above referenced filing. The Company contacted the SEC staff to request an extension of time to respond beyond the period indicated in the letter and was granted an extension to respond no later than December 14, 2023.
Please direct any comments or questions to me at 267-824-2827.
Sincerely,
Madrigal Pharmaceuticals, Inc.
/s/ Brian J. Lynch
Brian J. Lynch
Senior Vice President and General Counsel
